Akebia Therapeutics (AKBA) Current Assets (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Current Assets data on file, last reported at $243.5 million in Q1 2026.

• Current Assets for Q1 2026 came in at $243.5 million, up 19.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $243.5 million (up 19.48% YoY), and the FY2025 annual result was $253.0 million, up 122.22% from the prior year.
• Current Assets retreated to $243.5 million in Q1 2026 per AKBA's latest filing, from $253.0 million in the prior quarter.
• Over five years, Current Assets peaked at $308.2 million in Q2 2022 and troughed at $100.1 million in Q3 2024.
• A 5-year average of $184.7 million and a median of $185.2 million in 2022 frame the typical range for Current Assets.
• The sharpest annual moves came in 2023 and 2025: Current Assets sank 61.57% in 2023, then soared 158.03% in 2025.
• A 5-year view of Current Assets shows it stood at $185.2 million in 2022, then plunged by 36.2% to $118.1 million in 2023, then slipped by 3.65% to $113.8 million in 2024, then soared by 122.22% to $253.0 million in 2025, then declined by 3.75% to $243.5 million in 2026.
• Business Quant data shows AKBA's Current Assets at $243.5 million in Q1 2026, $253.0 million in Q4 2025, and $258.3 million in Q3 2025.